Drug Price Trends for PREVACID

« Back to Dashboard

Average Pharmacy Cost for PREVACID

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
PREVACID DR 30 MG CAPSULE	64764-0046-13	13.21423	EACH	2026-07-22
PREVACID DR 15 MG SOLUTAB	64764-0543-11	13.24954	EACH	2026-07-22
PREVACID DR 15 MG SOLUTAB	64764-0543-30	13.24954	EACH	2026-07-22
PREVACID DR 30 MG SOLUTAB	64764-0544-11	13.23518	EACH	2026-07-22
PREVACID DR 30 MG SOLUTAB	64764-0544-30	13.23518	EACH	2026-07-22
PREVACID DR 15 MG SOLUTAB	64764-0543-11	13.22400	EACH	2026-06-17

Prevalence, Market Position, and Revenue Trends for PREVACID (Lansoprazole)

Last updated: February 12, 2026

PREVACID (lansoprazole) is a proton pump inhibitor (PPI) used primarily for gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome. Its market has experienced shifts owing to generic entry, patent expirations, and competition from newer therapies.

---

Market Size and Key Drivers

• The global PPIs market was valued at approximately USD 14 billion in 2022, with PREVACID accounting for a significant share historically.
• The U.S. market historically contributed around 40% of global sales, driven by high prevalence of GERD—estimated at 20% of adults.
• The rise in GERD diagnoses and increased awareness sustain demand, but market saturation and generics limit revenue growth.

---

Patent Expiry and Generic Competition

• Original PREVACID patent protection expired in November 2010 in the U.S. and in 2012 in Europe.
• Generic lansoprazole launched shortly after, leading to a steep price decline.
• As of 2023, multiple U.S. generics compete, causing price erosion and reducing branded PREVACID revenue.

---

Pricing Trends and Market Share

• The brand price pre-patent expiry: approximately USD 3–4 per pill.
• Post-generic entry: prices fell to USD 0.50–1.00 per pill.
• The current market share of branded PREVACID is less than 5%, with generics dominating.

---

Future Price Projections

• With further market penetration of low-cost generics, FDA-approved biosimilars, or novel formulations, branded prices are unlikely to recover.
• Price stability may occur if new indications or formulations (e.g., controlled-release versions or combination therapies) are introduced.
• Estimated average retail price (ARP) in 2025: USD 0.75–1.50 per pill, barring new patent protections or innovations.
• Overall, revenue from PREVACID is declining; current annual income likely below USD 100 million globally, projected to decrease further absent new indications.

---

Regulatory and Patent Landscape

• Patent litigation and secondary patents in key markets have been exhausted.
• No current patent protection limits are active in major regions, facilitating generic competition.
• Patent applications for new formulations have been filed but have not yet led to market exclusivity for PREVACID.

---

Competitive Landscape

• Major generic producers: Teva, Sun Pharmaceuticals, Amneal.
• Alternative PPIs with similar efficacy—omeprazole, esomeprazole—capture larger market shares due to aggressive pricing.
• Rising popularity of H2 receptor antagonists (e.g., ranitidine, though many withdrawn due to safety concerns) reduces reliance on PPIs.

---

Implications for Stakeholders

• For pharmaceutical companies: opportunities exist for new indications or formulations.
• For investors: branded PREVACID's market potential is limited; revenue is in decline.
• For payers and healthcare providers: cost-effectiveness favors lower-cost generics and biosimilars.

---

Key Takeaways

• PREVACID's market has contracted significantly post-patent expiry due to extensive generic competition.
• Current revenue levels are low, with prices expected to stabilize or decline further.
• Future growth prospects depend on innovation, new indications, or formulation patents.

---

FAQs

1. What is the current primary use of PREVACID?
   It is mainly prescribed for GERD, erosive esophagitis, and Zollinger-Ellison syndrome.

2. Has PREVACID regained exclusivity or received new patents?
   As of 2023, no recent patents or exclusivity rights are in effect in major markets.

3. What are the main competitors for PREVACID?
   Other PPIs like omeprazole and esomeprazole, along with generic lansoprazole formulations.

4. What does the price trend for PREVACID look like?
   Significant decline post-generic entry, with prices stabilizing at lower levels.

5. Are there opportunities for PREVACID in the future?
   Potential exists if new formulations or indications are approved, allowing for patent protection and premium pricing.

---

Sources

1. MarketWatch. "Proton Pump Inhibitors Market Size," 2022.
2. FDA Patent and Exclusivity Data, 2023.
3. IQVIA. "Pharmaceutical Market Data," 2022.
4. EvaluatePharma. "Global Oncology and Gastrointestinal Markets," 2023.
5. FDA and EMA drug approval records, 2023.